Semaglutide in Treatment of Obesity

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

462

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

March 1, 2026

Conditions

Weight Management

Interventions

DRUG

HD1916

HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

DRUG

semaglutide

semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06604624 - Semaglutide in Treatment of Obesity | Biotech Hunter | Biotech Hunter